SOPHiA GENETICS (NASDAQ:SOPH) Issues Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) released its quarterly earnings data on Tuesday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04), Zacks reports. The company had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• Q1 results — revenue of $21.7M (+22% YoY), a record 108,000 genomic analyses, and a 75.4% adjusted gross margin, which management says demonstrates the platform’s scalability.
• Network and retention — 537 institutional customers across 75 countries and ~2.5M profiles since inception; net dollar retention rose to 117% with multiple >$1M ACV expansion deals, supporting in-account upsell momentum.
• Biopharma traction — accelerating engagement with partners including AstraZeneca and J&J, plus efforts to build a global CDx and real-world evidence offering that management expects will be a material growth driver.
• Outlook and profitability path — the company reaffirmed 2026 revenue guidance of $92–$94M (20–22% growth) and adjusted EBITDA loss guidance of $29–$32M, and expects to approach adjusted-EBITDA breakeven by end-2026 and turn positive in H2 2027.
• Risks and headwinds — ongoing Guardant patent litigation (Q1 legal expense ~$1.4M, net ~$700k after interim recoveries), Swiss franc FX translation pressure raising dollar-reported costs, softness in Latin America, and elevated Q1 cash burn of $19.5M despite $65.4M cash on hand.

SOPHiA GENETICS Stock Down 1.3%

SOPH stock traded down $0.07 during midday trading on Wednesday, hitting $5.00. The company’s stock had a trading volume of 40,957 shares, compared to its average volume of 165,372. The company has a market cap of $342.72 million, a PE ratio of -9.81 and a beta of 1.01. SOPHiA GENETICS has a 12 month low of $2.59 and a 12 month high of $5.70. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The firm’s 50-day moving average is $4.82 and its 200-day moving average is $4.78.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG reaffirmed a “buy” and raised its price target to $8, implying ~60% upside from current levels — this analyst support could attract buyers and provide upside momentum. BTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8
• Positive Sentiment: Q1 revenue grew 22% YoY to $21.7M and the company reported a record 108,000 genomic analyses on its SOPHiA DDM platform; adjusted gross margin remained strong and adjusted EBITDA loss modestly improved — operational growth signs that support longer?term value. SOPHiA GENETICS Reports First Quarter 2026 Results
• Neutral Sentiment: FY?2026 revenue guidance was set at $92.0M–$94.0M versus a consensus near $93.3M; management did not provide clear EPS guidance in the release — guidance roughly in line with expectations but not clearly bullish. Press Release / Slide Deck
• Neutral Sentiment: Earnings call and transcript are available for details on cadence, commercialization and product adoption — useful for investors parsing guidance cadence and management tone. Earnings Call Transcript
• Negative Sentiment: Management reported an EPS miss: ($0.27) vs. consensus ($0.23), and IFRS net loss widened to $19.3M; negative net margin and return on equity remain headwinds that can sap investor sentiment near term. MarketBeat Earnings Summary

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 43,129 shares of the stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total transaction of $213,919.84. Following the transaction, the chief executive officer directly owned 3,664,440 shares of the company’s stock, valued at $18,175,622.40. This represents a 1.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 193,859 shares of company stock worth $943,777. 4.88% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently bought and sold shares of SOPH. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter worth $49,000. Quadrature Capital Ltd purchased a new stake in SOPHiA GENETICS in the 4th quarter worth $54,000. XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $55,000. Susquehanna International Group LLP purchased a new position in shares of SOPHiA GENETICS during the third quarter valued at about $88,000. Finally, Polen Capital Management LLC purchased a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $102,000. 31.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on SOPH. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Finally, Guggenheim lifted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.